Search
Vanzacaftor
go.drugbank.com/drugs/DB18373ApprovedInvestigational], a CFTR potentiator, for the treatment of patients with responsive CFTR mutations. … Vanzacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) corrector.
TORL-2-307
go.drugbank.com/drugs/DB18376ExperimentalTORL-2307 is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against claudin 18.2 (CLDN18.2) being investigated for the treatment of gastric and pancreatic cancer.
XTMAB-16
go.drugbank.com/drugs/DB18380InvestigationalXTMAB-16 is a monoclonal antibody directed against tumour necrosis factor-alpha (TNFα).
IVT-8086
go.drugbank.com/drugs/DB18381ExperimentalIVT-8086 is a humanized secreted frizzled-related protein-2 monoclonal antibody.
CAN-106
go.drugbank.com/drugs/DB18389InvestigationalCAN-106 a novel, long-acting monoclonal antibody directed against human complement C5.
LAVA-051
go.drugbank.com/drugs/DB18395InvestigationalLAVA-051 is a humanized Vγ9Vδ2-T cell-engaging bispecific antibody.
IFx-Hu2.0
go.drugbank.com/drugs/DB18396InvestigationalIt is composed of plasmid DNA encoding the streptococcal membrane protein, Emm55, contained within a cationic polymer.
Synonyms: Immunotherapeutic vaccine consisting of pAc/emm55, a plasmid DNA (pDNA), which codes for a modified immunogenic, streptococcal Emm55 protein, complexed with in vivo-jetPEI® polymer-based reagent linearKP1237
go.drugbank.com/drugs/DB18401ExperimentalKP1237 is a antibody-redirecting molecule composed of two binding sites (a CD38 binder and a universal antibody binding terminus binder) connected by a linker chain.
rAAV9-hNAGLU
go.drugbank.com/drugs/DB18415ExperimentalrAAV9-hNAGLU consists of a recombinant AAV9 expressing human alpha-N-acetylglucosaminidase.
PF-05230907
go.drugbank.com/drugs/DB18417InvestigationalPF-05230907 is a recombinant activated Factor X variant.
Synonyms: RECOMBINANT FACTOR XA VARIANT FXAI16L